An FDA advisory committee has voted that Amgen’s confirmatory phase 3 trial for KRAS inhibitor Lumakras is not enough to support full approval, but it seems unlikely that the first-to-market therapy ...

Welcome to your gateway to the IMF's global economic data. Our new data portal provides streamlined access to timely, reliable, and easy-to-understand macroeconomic and financial data. While the ...

Acadia Pharma's attempts to extend the indications of its Nuplazid drug in the US to include Alzheimer's disease-related psychosis have suffered another major setback. Nuplazid (pimavanserin) is ...